Australia markets open in 6 hours 15 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.21-0.06 (-0.24%)
As of 11:45AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.60B
Enterprise value 2.25B
Trailing P/E 31.59
Forward P/E 26.18
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.35
Price/book (mrq)5.64
Enterprise value/revenue 5.00
Enterprise value/EBITDA 22.37

Trading information

Stock price history

Beta (5Y monthly) 0.43
52-week change 3-1.13%
S&P500 52-week change 314.98%
52-week high 334.28
52-week low 317.86
50-day moving average 327.61
200-day moving average 325.30

Share statistics

Avg vol (3-month) 3750.9k
Avg vol (10-day) 3566.93k
Shares outstanding 5103.08M
Implied shares outstanding 6103.08M
Float 884.65M
% held by insiders 111.61%
% held by institutions 186.56%
Shares short (14 Nov 2023) 415.27M
Short ratio (14 Nov 2023) 419.18
Short % of float (14 Nov 2023) 423.87%
Short % of shares outstanding (14 Nov 2023) 414.81%
Shares short (prior month 12 Oct 2023) 414.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 20.31%
Operating margin (ttm)25.22%

Management effectiveness

Return on assets (ttm)10.88%
Return on equity (ttm)19.55%

Income statement

Revenue (ttm)450.03M
Revenue per share (ttm)4.29
Quarterly revenue growth (yoy)21.50%
Gross profit (ttm)396.47M
Net income avi to common (ttm)90.89M
Diluted EPS (ttm)0.80
Quarterly earnings growth (yoy)-9.30%

Balance sheet

Total cash (mrq)355.22M
Total cash per share (mrq)3.45
Total debt (mrq)225k
Total debt/equity (mrq)0.05%
Current ratio (mrq)3.54
Book value per share (mrq)4.48

Cash flow statement

Operating cash flow (ttm)154.54M
Levered free cash flow (ttm)160.15M